Archie Tse

Brunswick (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

25h-index4.4kcitations124works2.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer therapeutics and mechanisms(35), Cancer-related Molecular Pathways(26), Cancer Immunotherapy and Biomarkers(23), DNA Repair Mechanisms(12), Lung Cancer Treatments and Mutations(12)

Publications124 total

Spatial biomarker-driven deep learning model via digital pathology predicts response to PI3K inhibitor buparlisib in head and neck squamous cell carcinoma
2025Open Access
LBA48 BURAN: A phase III study of buparlisib (BUP) plus paclitaxel (PAC) in patients with PD-1(PD-L1)-pretreated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Annals of Oncology·2025· 1 citedOpen Access
Buparlisib and Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Immunogenomic Biomarkers of Efficacy from the BERIL-1 Study
Targeted Oncology·2025· 4 cited
Comprehensive population pharmacokinetic modelling of sugemalimab, an anti‐programmed death‐ligand 1 (PD‐L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I–III studies
British Journal of Clinical Pharmacology·2024· 4 cited
A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma
Targeted Oncology·2024· 2 cited
Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study
Cancer·2024· 2 citedOpen Access
Tumor growth <scp>inhibition‐overall</scp> survival modeling in <scp>non‐small</scp> cell lung cancer: A case study from <scp>GEMSTONE</scp>‐302
CPT Pharmacometrics & Systems Pharmacology·2023· 10 citedOpen Access
Clinical pharmacokinetics and pharmacodynamics of ivosidenib in Chinese patients with relapsed or refractory IDH1-mutated acute myeloid leukemia
European Journal of Clinical Pharmacology·2023· 1 cited
A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer
British Journal of Cancer·2023· 6 citedOpen Access
Can a propensity score matching method be applied to assessing efficacy from <scp>single‐arm proof‐of‐concept</scp> trials in oncology?
CPT Pharmacometrics & Systems Pharmacology·2023· 7 citedOpen Access
Supplementary Data from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Data from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S1 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S2 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S1 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Table S1 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Supplementary Data from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Table S1 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S2 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S3 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Gary K. Schwartz(17), David P. Kelsen(9), Robert A. Lefkowitz(7), Richard D. Carvajal(6), Mithat Gönen(6), Manish A. Shah(5), Eileen M. O’Reilly(5), Kevin J. Harrington(4), Aurélien Marabelle(4), Tahir Sheikh(4), Richard G. Moran(4), Nancy E. Kemeny(3), Anuradha Khilnani(3), Lawrence H. Schwartz(3), Jayasree S. Nair(3), Nian Wu(3), Jeremy Kortmansky(3), G. K. Schwartz(3), Yucheng Sheng(3), Jinru Shia(2)